Recent News and Industry Developments

What’s Happening in the Medicare Advantage World
Advisories | News | What’s Happening in the Medicare Advantage World

August 23, 2018 The Medicare Advantage sector is experiencing steady growth. From the increasing number of enrolled beneficiaries, to health insurers investing in this privatized version of traditional Medicare, to… Read more »

MALPRACTICE POINTERS WHEN PRESCRIBING DRUGS FOR OFF-LABEL USES
Advisories | News | MALPRACTICE POINTERS WHEN PRESCRIBING DRUGS FOR OFF-LABEL USES

August 21, 2018 Unlike the regulatory prohibitions against drug and device manufacturers advertising and/or promoting use of their products off-label, doctors are free to responsibly use FDA-regulated products outside of… Read more »

New OIG Report Highlights Risk of Fraud and Abuse at Compounding Pharmacies and Recommends the Launch of Further Investigations
Advisories | News | New OIG Report Highlights Risk of Fraud and Abuse at Compounding Pharmacies and Recommends the Launch of Further Investigations

August 13, 2018 The U.S. Department of Health and Human Services (HHS), Office of Inspector General (OIG) released a new report  this month highlighting its concern with the enormous increase… Read more »

VIRGINIA BOARD OF MEDICINE UPDATE: NEW LICENSURE BY ENDORSEMENT REGULATIONS, LEGISLATIVE ACTIONS, AND FINAL OPIOID AND BUPRENORPHINE REGULATIONS
Advisories | News | VIRGINIA BOARD OF MEDICINE UPDATE: NEW LICENSURE BY ENDORSEMENT REGULATIONS, LEGISLATIVE ACTIONS, AND FINAL OPIOID AND BUPRENORPHINE REGULATIONS

August 8, 2018 On September 5, 2018, the Virginia Board of Medicine’s (“BOM”) “Licensure by Endorsement” regulations will become effective.  These regulations, published in the Virginia Register on August 8,… Read more »

PREPARING FOR NEW JOINT COMMISSION ACCREDITATION AND CERTIFICATION STANDARDS: IMPLICATIONS FOR HOSPITALS AND HOME CARE ORGANIZATIONS ENGAGED IN STERILE MEDICATION COMPOUNDING
News | PREPARING FOR NEW JOINT COMMISSION ACCREDITATION AND CERTIFICATION STANDARDS: IMPLICATIONS FOR HOSPITALS AND HOME CARE ORGANIZATIONS ENGAGED IN STERILE MEDICATION COMPOUNDING

July 30, 2018 As part of its new series of monthly updates entitled “4-1-1 on Survey Enhancements” the Joint Commission has identified sterile medication compounding as its first high-risk area… Read more »

FLORIDA FEDERAL COURT RULES DECLARATORY JUDGMENT ACTION AGAINST HHS REGARDING THE PSQIA CAN PROCEED
Advisories | News | FLORIDA FEDERAL COURT RULES DECLARATORY JUDGMENT ACTION AGAINST HHS REGARDING THE PSQIA CAN PROCEED

July 25, 2018 A Florida federal district court has held that Tampa General Hospital’s declaratory judgment action against the Secretary of the Department of Health and Human Services can proceed. … Read more »

ILLINOIS APPELLATE COURT RECOGNIZES PSQIA PROTECTIONS, OVERTURNING ORDER TO PRODUCE AND PRIOR CONTEMPT FINDING
Advisories | News | ILLINOIS APPELLATE COURT RECOGNIZES PSQIA PROTECTIONS, OVERTURNING ORDER TO PRODUCE AND PRIOR CONTEMPT FINDING

July 2, 2018 An Illinois hospital has successfully appealed a trial court order requiring it to produce confidential and privileged Patient Safety Work Product (“PSWP”) documents and finding it in… Read more »

Rod Dillman and Jennifer Stevens Prevail with Defense Verdict in Repair and Revision Surgery Case
Verdicts | Rod Dillman and Jennifer Stevens Prevail with Defense Verdict in Repair and Revision Surgery Case

Rod Dillman and Jennifer Stevens successfully secured a defense verdict for a trauma surgeon on May 25, 2018 after a five-day trial in Norfolk Circuit Court.  The plaintiff alleged negligent… Read more »

After a Two-Hour Deliberation, Rod Dillman and Brett Saunders Obtain a Defense Verdict
Verdicts | After a Two-Hour Deliberation, Rod Dillman and Brett Saunders Obtain a Defense Verdict

In the early morning hours of December 24, 2014, a patient was 33 weeks pregnant and complaining of severe abdominal pain and contractions. Upon examination by the nursing staff, no… Read more »

INVESTIGATIONAL DRUG PRODUCTS: REGULATORY CHANGES THAT MAY HAVE IMPLICATIONS FOR YOUR CLINICAL TRIAL CONDUCT SITES
Advisories | News | INVESTIGATIONAL DRUG PRODUCTS: REGULATORY CHANGES THAT MAY HAVE IMPLICATIONS FOR YOUR CLINICAL TRIAL CONDUCT SITES

Navigating compliance requirements in a space co-regulated at both the federal and state level can be complex and challenging. Recent changes in how the Virginia Board of Pharmacy classifies investigational… Read more »

THE OPIOID CRISIS RESPONSE ACT OF 2018: POTENTIAL HEALTHCARE IMPLICATIONS
Advisories | News | THE OPIOID CRISIS RESPONSE ACT OF 2018: POTENTIAL HEALTHCARE IMPLICATIONS

THE OPIOID CRISIS RESPONSE ACT OF 2018: POTENTIAL HEALTHCARE IMPLICATIONS Elizabeth Whalley Buono, a Director at Hancock, Daniel & Johnson, P.C. (Hancock Daniel), has been serving as an expert panel… Read more »

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19